Wells Fargo
AEGR

Wells Fargo’s Aegerion Pharmaceuticals AEGR Stock Holding History

Wells Fargo’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-38
Closed – – 6518
2016
Q2 		$0 Sell
38
-9,332
-100% -$21.3K ﹤0.01% 6571
2016
Q1 		$34K Buy
9,370
+1,071
+13% +$6.63K ﹤0.01% 5361
2015
Q4 		$83K Sell
8,299
-1,166
-12% -$14K ﹤0.01% 5054
2015
Q3 		$129K Sell
9,465
-25
-0.3% -$445 ﹤0.01% 4719
2015
Q2 		$180K Buy
9,490
+6,322
+200% +$137K ﹤0.01% 4671
2015
Q1 		$83K Buy
3,168
+185
+6% +$4.71K ﹤0.01% 4820
2014
Q4 		$63K Buy
2,983
+69
+2% +$1.74K ﹤0.01% 4929
2014
Q3 		$97K Sell
2,914
-6,189
-68% -$192K ﹤0.01% 4674
2014
Q2 		$291K Sell
9,103
-16,104
-64% -$600K ﹤0.01% 4197
2014
Q1 		$1.16M Sell
25,207
-201
-0.8% -$11.8K ﹤0.01% 3383
2013
Q4 		$1.8M Sell
25,408
-531,565
-95% -$40.6M ﹤0.01% 3011
2013
Q3 		$47.8M Buy
556,973
+452,750
+434% +$38.4M 0.02% 715
2013
Q2 		$6.6M Buy
+104,223
New +$5.53M ﹤0.01% 1891

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Wells Fargo's AEGR Position: Q3 2016 in Review

Wells Fargo sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 38 shares.

Wells Fargo first reported a position in AEGR in Q2 2013 and held it in 13 quarters. The position peaked at $47.8M in Q3 2013. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

  • Wells Fargo reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Wells Fargo sold 38 Aegerion Pharmaceuticals shares in Q3 2016.
  • Wells Fargo first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Wells Fargo's Aegerion Pharmaceuticals position peaked at $47.8M in Q3 2013.
  • 58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on Wells Fargo's 13F filing for Q3 2016, filed 31 Oct 2016.